Filing Details

Accession Number:
0001209191-20-043191
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-21 16:18:05
Reporting Period:
2020-07-16
Accepted Time:
2020-07-21 16:18:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1762303 Avita Therapeutics Inc. RCEL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1404254 David Mcintyre C/o Avita Therapeutics, Inc.
28159 Avenue Stanford, Suite 220
Valencia CA 91355
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-16 300 $23.85 500 No 4 P Direct
Common Stock Acquisiton 2020-07-17 393 $22.70 893 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. Reflects 1,500 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of Common Stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person purchased 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from A$6.81 to A$6.83, or US$23.80 to $23.90 using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of CDIs purchased at each separate price within the ranges set forth in this footnote to this Form 4.
  3. Includes 1,500 CDIs, which translate into 300 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock.
  4. The Reporting Person purchased 1,966 CDIs, which translate into 393 shares of Common Stock as set forth above.
  5. Converted from a price of A$6.5 per CDI using the 5:1 CDI conversion ratio and the currency exchange rate as in effect on the date of the transaction.
  6. Includes 3,466 CDIs, which translate into 693 shares of Common Stock as set forth above as well as 200 shares of previously reported Common Stock.